- Home
- TZOO vs CTNM Comparison
TZOO vs CTNM Comparison
Compare TZOO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZOO
- CTNM
- Stock Information
- Founded
- TZOO 1998
- CTNM 2009
- Country
- TZOO United States
- CTNM United States
- Employees
- TZOO N/A
- CTNM N/A
- Industry
- TZOO Advertising
- CTNM
- Sector
- TZOO Consumer Discretionary
- CTNM
- Exchange
- TZOO Nasdaq
- CTNM Nasdaq
- Market Cap
- TZOO 136.1M
- CTNM 122.9M
- IPO Year
- TZOO 2002
- CTNM 2024
- Fundamental
- Price
- TZOO $13.00
- CTNM $3.88
- Analyst Decision
- TZOO Strong Buy
- CTNM Strong Buy
- Analyst Count
- TZOO 4
- CTNM 4
- Target Price
- TZOO $23.50
- CTNM $22.50
- AVG Volume (30 Days)
- TZOO 134.4K
- CTNM 213.2K
- Earning Date
- TZOO 07-24-2025
- CTNM 08-12-2025
- Dividend Yield
- TZOO N/A
- CTNM N/A
- EPS Growth
- TZOO 11.63
- CTNM N/A
- EPS
- TZOO 1.01
- CTNM N/A
- Revenue
- TZOO $85,057,000.00
- CTNM N/A
- Revenue This Year
- TZOO $16.97
- CTNM N/A
- Revenue Next Year
- TZOO $23.72
- CTNM N/A
- P/E Ratio
- TZOO $13.23
- CTNM N/A
- Revenue Growth
- TZOO 0.23
- CTNM N/A
- 52 Week Low
- TZOO $7.12
- CTNM $3.35
- 52 Week High
- TZOO $24.85
- CTNM $21.92
- Technical
- Relative Strength Index (RSI)
- TZOO 54.43
- CTNM N/A
- Support Level
- TZOO $12.47
- CTNM N/A
- Resistance Level
- TZOO $13.65
- CTNM N/A
- Average True Range (ATR)
- TZOO 0.53
- CTNM 0.00
- MACD
- TZOO 0.10
- CTNM 0.00
- Stochastic Oscillator
- TZOO 89.13
- CTNM 0.00
About TZOO Travelzoo
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.